By contrast , there were no significant differences by treatment group for patients with EGFR Leu@Arg-positive tumours in either trial : in LUX-Lung @ , median overall survival was @ months ( @-@ @ ) in the afatinib group versus @ months ( @-not estimable ) in the chemotherapy group ( HR @ , @ % CI @-@ @ , p = @ ) ; in LUX-Lung @ , it was @ months ( @ % CI @-@ @ ) versus @ months ( @-@ @ ) , respectively ( HR @ , @ % CI @-@ @ , p = @ ) .